Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Atacama Labs Oy

This article was originally published in Start Up

Executive Summary

Atacama Labs aims to create better oral solid-dosage forms using a pneumatic dry granulation process that it claims can granulate virtually any active drug ingredient. To prove the worth of its technology to potential clients, Atacama has applied its method to two drugs that are notoriously difficult to dry-formulate: paracetamol for pain and metformin for diabetes. That mission has been accomplished, and now Atacama is inviting drug companies to send it proprietary compounds that they deem their most difficult to formulate.

You may also be interested in...



The Drug Delivery Road Gets Tougher

While making money in drug delivery has always been tougher than its boosters have promised, this year's been ugly in new and disturbing ways. The key lessons of Pfizer's abandonment of inhaled insulin and Impax's patent assault on Endo's Opana are that partners are less reliable; the products need to be medically superior to existing ones, not simply more convenient; and generic companies are making inroads into the main bastion of drug-delivery success -- spec pharma.

Super-Specialist CROs: Commercializing Pharma R&D Expertise

Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.

Spero Therapeutics: Remodeling Antibiotics

Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.

Topics

Related Companies

UsernamePublicRestriction

Register

OM011382

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel